Your browser doesn't support javascript.
loading
Cost-effective analysis of hepatitis A vaccination in Kerala state, India.
Gurav, Yogesh Krishnarao; Bagepally, Bhavani Shankara; Chitpim, Natthakan; Sobhonslidsuk, Abhasnee; Gupte, Mohan Digambar; Chaikledkaew, Usa; Thakkinstian, Ammarin; Thavorncharoensap, Montarat.
Afiliación
  • Gurav YK; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
  • Bagepally BS; Health Technology Assessment Group, ICMR-National Institute of Virology, Pune, Maharashtra, India.
  • Chitpim N; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
  • Sobhonslidsuk A; Division of Non-Communicable Diseases, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.
  • Gupte MD; Social, Economic and Administrative Pharmacy Graduate Program, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
  • Chaikledkaew U; Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Thakkinstian A; ICMR- National Institute of Epidemiology, Chennai, Tamil Nadu, India.
  • Thavorncharoensap M; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
PLoS One ; 19(6): e0306293, 2024.
Article en En | MEDLINE | ID: mdl-38935781
ABSTRACT
Several hepatitis A outbreaks have recently been reported in Kerala state, India. To inform coverage decision of hepatitis A vaccine in Kerala, this study aimed to examine the cost-effectiveness of 1) hepatitis A vaccination among children aged 1 year and individuals aged 15 years, and 2) serological screening of individuals aged 15 years and vaccination of susceptible as compared to no vaccination or vaccination without serological screening. Both live attenuated hepatitis A vaccine and inactivated hepatitis A vaccine were considered in the analysis. A combination of decision tree and Markov models with a cycle length of one year was employed to estimate costs and benefits of different vaccination strategies. Analysis were based on both societal and payer perspectives. The lifetime costs and outcomes were discounted by 3%. Our findings indicated that all strategies were cost-saving for both societal and payer perspectives. Moreover, budget impact analysis revealed that vaccination without screening among individuals aged 15 years could save the government's budget by reducing treatment cost of hepatitis A. Our cost-effectiveness evidence supports the inclusion of hepatitis A vaccination into the vaccination program for children aged 1 year and individuals aged 15 years in Kerala state, India.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunación / Análisis Costo-Beneficio / Vacunas contra la Hepatitis A / Hepatitis A Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Asia Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Tailandia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunación / Análisis Costo-Beneficio / Vacunas contra la Hepatitis A / Hepatitis A Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Asia Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Tailandia Pais de publicación: Estados Unidos